Artikel ; Online: Administration of Routine Antenatal Anti-D Prophylaxis (RAADP) in Wellington, Aotearoa: is our practice equitable?
The New Zealand medical journal
2023 Band 136, Heft 1581, Seite(n) 51–55
Abstract: Aim: To assess local compliance with Routine Antenatal Anti-D Prophylaxis (RAADP) guidelines and to determine if its administration is equitable in Wellington, Aotearoa New Zealand.: Methods: A retrospective 6-month audit of people birthing in ... ...
Abstract | Aim: To assess local compliance with Routine Antenatal Anti-D Prophylaxis (RAADP) guidelines and to determine if its administration is equitable in Wellington, Aotearoa New Zealand. Methods: A retrospective 6-month audit of people birthing in Wellington maternity units. Rhesus-negative people were identified and electronic heath records reviewed. Results: Two hundred and nine out of 1,881 (11%) of people birthing were Rhesus-negative. Two hundred and five people were included in the audit. Three people were excluded as they birthed prior to 28 weeks, and one was already isoimmunised. One became isoimmunised during pregnancy. Eighty-three out of 205 (40%) received RAADP as per guidelines. Factors that made it more likely for people to receive RAADP were private obstetrician care (78% versus 34%, p<0.01), living closer to hospital (p<0.01) and birthing in Wellington Hospital (43% versus 11% in a primary unit, p<0.01). There is no evidence that management was influenced by ethnicity, mode of birth, parity, age or attendance at a hospital antenatal clinic. Conclusion: RAADP guidelines are not being followed and some subgroups are disproportionately affected. There is evidence of harm, with one person becoming isoimmunised during pregnancy. Simplifying local protocols, establishing more sites for RAADP administration such as pharmacies or primary units and improving staff and patient education could help to address these inequities. |
---|---|
Mesh-Begriff(e) | Female ; Pregnancy ; Humans ; New Zealand ; Retrospective Studies ; Ambulatory Care Facilities |
Chemische Substanzen | 4-ribitylamino-5-amino-2,6-dihydroxypyrimidine ; RHO(D) antibody |
Sprache | Englisch |
Erscheinungsdatum | 2023-08-25 |
Erscheinungsland | New Zealand |
Dokumenttyp | Journal Article |
ZDB-ID | 390590-1 |
ISSN | 1175-8716 ; 0028-8446 ; 0110-7704 |
ISSN (online) | 1175-8716 |
ISSN | 0028-8446 ; 0110-7704 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Ua VI Zs.396: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.